Dr. Reddy’s CDMO arm Aurigene inks long-term manufacturing pact with global pharma major
Aurigene Pharmaceutical Services, a subsidiary of Dr. Reddy’s Laboratories, has signed a long-term manufacturing agreement with a global pharmaceutical company. The deal involves producing over 20 drug products, with revenue expected to begin in 2028.
Why it matters
This partnership strengthens India's position as a global hub for pharmaceutical contract manufacturing and research.
Contract research, development and manufacturing organisation Aurigene Pharmaceutical Services, a subsidiary of Dr. Reddy’s Laboratories, has entered into a long-term manufacturing and supply agreement (MSA) with a leading global pharmaceutical company.
Under the agreement, Aurigene will undertake commercial drug-product manufacturing and supply for a diversified portfolio targeting markets across the U.S., Europe, Canada and emerging markets. The identity of the global pharmaceutical company has not been disclosed due to confidentiality obligations.
The initial portfolio comprises more than 20 products across sterile injectables, biologics and topical formulations, which will be manufactured at Aurigene’s facilities in India.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in